Researchers have solved the three-dimensional structure of a key biological receptor. The finding has the potential to speed drug discovery in many areas because it enables chemists to better examine and design molecules for use in experimental drugs.
An international team of scientists have discovered new treatments for a rare and potentially lethal childhood disease that is the clinical opposite of diabetes mellitus.
Euthymics Bioscience, Inc. has initiated a phase 2b/3a study of its lead product candidate EB-1010, a novel serotonin-preferring triple reuptake inhibitor, for the treatment of major depressive disorder.
Cornerstone Pharmaceuticals, Inc., a leader in cancer metabolism-based therapeutics, announced encouraging results of a preclinical toxicity study of azide drug-loaded Emulsiphan nano emulsions conducted with the National Cancer Institute.
A new study suggests that combining two experimental anticancer peptide agents might simultaneously block formation of new tumor blood vessels while also inhibiting the growth of tumor cells.
Specialty drug developer CPEX Pharmaceuticals Inc. said it received an unsolicited recapitalization offer from Mangrove Partners. CPEX said its board of directors will review the terms of the Mangrove offer as soon as practical.
EMD Millipore announced the introduction of the Samplicity Filtration System, an innovative new technology that provides a convenient, high throughput alternative to syringe-tip filters when preparing samples for chromatography.
Thermo Fisher Scientific Inc. announced new ExactFinder software for its Exactive benchtop LC-MS system. The new software offers clinical research laboratories a single streamlined data processing, review and reporting workflow.
Progenics Pharmaceuticals Inc. reported a wider fourth-quarter loss compared to a year ago, when it received a large payment from a former partner.
Incyte Corp. said its main drug candidate met its goal in a second-late stage clinical trial, as the drug reduced swelling of the spleen in patients with a rare blood cancer.
Drug and medical device maker Abbott Laboratories lowered Chief Executive Miles White's total compensation by 8 percent last year, as the company's its stock slid on concerns about future growth.
Aegerion Pharmaceuticals has received federal orphan drug status for its lead candidate, a treatment for people with severe lipid disorders. Orphan drug status is given to drugs that treat diseases or conditions that affect fewer than 200,000 people.
Amylin Pharmaceuticals Inc. and Takeda Pharmaceutical Co. Ltd. said they have suspended a mid-stage clinical trial of a combination obesity treatment to investigate a new "antibody-related laboratory finding" with one of the drugs.
A potential Parkinson's disease treatment from Impax Laboratories Inc. could generate as much as $400 million in annual U.S. sales, according to a Collins Stewart analyst who raised her price target for the stock.
Pluristem Therapeutics, Inc. and New York University Medical Center announced the formation of a partnership to study the use of Pluristem’s proprietary placenta-derived PLX cells for the treatment of diabetic foot ulcers.